Tegretol Oral Suspension 2%: Update to the posology, method of administration, and limitation of use in neonates

A Dear Healthcare Professional Letter has been issued by Novartis (Singapore) Pte Ltd to inform healthcare professionals of updates to the posology, method of administration, and limitation of use in neonates with Tegretol Oral Suspension 2% (OS). The revised maximum daily dose for Tegretol OS is recommended to be limited to 1200 mg/day. This recommendation is initiated to limit the amount of sorbitol intake given current constraints in sourcing sorbitol batches compliant with appropriate specifications. In addition, Tegretol OS is no longer recommended for neonates (below 4 weeks of age for term babies or 44 weeks post-menstrual age for pre-term babies) due to the amount of propylene glycol in this formulation. Please refer to the letter for details.

Healthcare professional, Industry member, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Nov 2024

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.